Welcome to our dedicated page for Hims & Hers Health news (Ticker: HIMS), a resource for investors and traders seeking the latest updates and insights on Hims & Hers Health stock.
Hims & Hers Health, Inc. reports news about its consumer telehealth platform, which connects customers with providers and offers treatment options across areas such as sexual health, hair loss, skin care, mental health and weight loss. Company updates commonly cover prescription access, FDA-approved GLP-1 weight loss medications, platform memberships, subscriber benefits and health-and-wellness partner programs.
Recurring developments also include operating and financial results, conference participation, board and executive appointments, shareholder voting matters, governance updates and clinical or regulatory disclosures tied to products available through the Hims and Hers platform.
Hims & Hers (NYSE:HIMS) expanded its Hims & Hers Benefits program, adding eight new partners across nutrition, fitness, women’s health, metabolic monitoring, and connected wellness. The lineup now includes iFIT, Ladder, MyFitnessPal, HelloFresh, Factor, Flo Health, Natural Cycles, PVOLVE Studios, Dexcom’s Stelo, Prenuvo, and Eight Sleep.
The program now offers 10 ways for active subscribers to support whole-body health, including discounted subscriptions, free trial periods, and meal offers. According to Hims & Hers, it does not profit from these benefits and passes 100% of negotiated value directly to active subscribers, who can access them immediately.
Hims & Hers (NYSE:HIMS) launched access to generic semaglutide for eligible customers in Canada, offering GLP-1-based personalised treatment plans starting at $149/month CAD. Plans combine medication, unlimited Care Team support, and evidence-informed guidance on nutrition, movement, and sleep, delivered by Canadian healthcare providers.
Generic semaglutide is authorized by Health Canada for Type 2 diabetes and may be prescribed off-label for weight management at a provider’s discretion.
Hims & Hers (NYSE:HIMS) launched access to generic semaglutide in Canada, its first international generic GLP-1 offering. Personalized weight-management treatment plans start at $149 CAD/month, aiming to expand access to affordable GLP-1 therapies.
Canadian patients receive care from local providers with ongoing support and lifestyle resources.
Hims & Hers (NYSE:HIMS) priced an upsized $350 million 0.00% convertible senior notes offering due 2032 to qualified institutional buyers under Rule 144A. The notes, upsized from $300 million, carry an initial conversion price of $29.53, a 32.5% premium to the May 18, 2026 share price.
Estimated net proceeds of $338.5–$389.5 million will support international expansion, the proposed Eucalyptus acquisition, technology and fulfillment investments, and AI platform scaling. About $32 million will fund capped call transactions, initially capped at $50.15 per share to help limit dilution on conversion.
Hims & Hers Health (NYSE:HIMS) plans a private offering of $300 million convertible senior notes due June 1, 2032, with an option for an additional $45 million.
According to Hims & Hers, proceeds will support international expansion, the proposed Eucalyptus acquisition, AI and infrastructure investment, capped call costs, and general corporate purposes.
Hims & Hers (NYSE:HIMS) reported Q1 2026 revenue of $608.1 million, up 4% year-over-year, with subscribers rising 9% to about 2.6 million. Gross margin was 65%.
The company recorded a $92.1 million net loss, Adjusted EBITDA of $44.3 million, and Free Cash Flow of $53.0 million. Operating cash flow was $89.4 million. Full-year 2026 guidance is $2.8–$3.0 billion in revenue and $275–$350 million in Adjusted EBITDA, excluding the proposed Eucalyptus acquisition.
Hims & Hers (NYSE: HIMS) nominated marketing executive Kofi Amoo-Gottfried for election to its board at the 2026 annual meeting in June. If elected, he would join a board of medical, tech, and consumer experts. The company also listed returning directors and said the board will shrink to 9 members.
Two long-serving directors will not be up for re-election, and Dr. Pat Carroll will remain Global Chief Medical Officer.
Hims & Hers (NYSE: HIMS) will report first quarter 2026 financial results after market close on May 11, 2026 and will host a live conference call at 5:00 p.m. ET the same day.
Dial-in numbers and conference ID 1704296 were provided, and a live audio webcast will be available at https://investors.hims.com and archived for one year. Management will also participate in the Evercore TMT Conference on June 2, 2026 in San Francisco.
Hims & Hers (NYSE: HIMS) announced availability of Novo Nordisk’s FDA-approved GLP-1 medications to eligible customers starting March 26, 2026, including the Wegovy pill, multiple semaglutide injection doses, and Ozempic pens.
Prices start at $149 per month; a new weight-loss membership begins at $39 first month, then $149 monthly. Providers determine clinical eligibility and may prescribe compounded GLP-1s when clinically necessary.
Hims & Hers (NYSE: HIMS) announced the appointment of Kathryn Beiser as Chief Communications Officer on March 11, 2026. Beiser will lead external and internal communications, report to CEO Andrew Dudum, and focus on brand building as the company pursues domestic and international growth.
Beiser previously held senior communications roles at Eli Lilly, Kaiser Permanente, Discover, and Edelman and will support the company’s consumer-focused growth and stakeholder engagement efforts.